Targeted Radionuclide Therapy of Human Tumors

Targeted radionuclide therapy is one of the most intensively developing directions of nuclear medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy causes less collateral damage to normal tissues and allows targeted drug delivery to a clinically diagnosed neoplastic malformations, as well as metastasized cells and cellular clusters, thus providing systemic therapy of cancer. The methods of targeted radionuclide therapy are based on the use of molecular carriers of radionuclides with high affinity to antigens on the surface of tumor cells. The potential of targeted radionuclide therapy has markedly grown nowadays due to the expanded knowledge base in cancer biology, bioengineering, and radiochemistry. In this review, progress in the radionuclide therapy of hematological malignancies and approaches for treatment of solid tumors is addressed.

• Publication year

  2015

• Venue

  International Journal of Molecular Sciences

• Publication date

  2015-12-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/ijms17010033PMID 26729091PMCID 4730279
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarkers for immunotherapy in genitourinary malignancies.

  2016influential reference
• 177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors : Results of the Phase III NETTER-1 Trial

  2016cited by this paper
• Impact of Whole‐Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131I‐Metaiodobenzylguanidine (MIBG)

  2016cited by this paper
• Introduction to Radiobiology of Targeted Radionuclide Therapy

  2015cited by this paper
• Targeted radionuclide therapies for pancreatic cancer

  2015cited by this paper
• Patient-Specific Dosimetry Using Pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) Dynamic PET/CT Imaging Before [131I]mIBG Targeted Radionuclide Therapy for Neuroblastoma

  2015cited by this paper
• Radioimmunotherapy of human tumours

  2015cited by this paper
• Building better monoclonal antibody-based therapeutics

  2015cited by this paper
• Prescribing Information

  2015cited by this paper
• Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.

  2015cited by this paper
• Multifunctional nanoparticles for use in theranostic applications

  2015cited by this paper
• A pretargeting system for tumor PET imaging and radioimmunotherapy

  2015cited by this paper
• Monoclonal antibodies in acute lymphoblastic leukemia.

  2015cited by this paper
• Radiotherapy and immunogenic cell death.

  2015cited by this paper
• Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).

  2015cited by this paper
• Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.

  2015cited by this paper
• New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.

  2015cited by this paper
• Radioimmunotherapy of human tumours

  2015influential reference
• Radioprotective substances: History, trends and prospects

  2015cited by this paper
• [Radioprotectors: History, Trends and Prospects].

  2015cited by this paper
• Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective

  2015cited by this paper
• Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

  2015cited by this paper
• A practical approach to diagnose soft tissue myeloid sarcoma preceding or coinciding with acute myeloid leukemia.

  2014cited by this paper
• Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma

  2014cited by this paper
• Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.

  2014cited by this paper
• Radioimmunotherapy with α-particle-emitting radionuclides.

  2014cited by this paper
• Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.

  2014cited by this paper
• Bone-Seeking Radiopharmaceuticals for Treatment of Osseous Metastases, Part 1: α Therapy with 223Ra-Dichloride

  2014cited by this paper
• Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma.

  2014cited by this paper
• Systemic Targeted Alpha Radiotherapy for Cancer - A Review

  2014cited by this paper
• CD5- and CD23-positive splenic diffuse large B-cell lymphoma with very low CD20 expression.

  2014cited by this paper
• Radiolabeled Apoptosis Imaging Agents for Early Detection of Response to Therapy

  2014cited by this paper
• Radioimmunoconjugates for the treatment of cancer.

  2014cited by this paper
• Therapeutic radionuclides in nuclear medicine: current and future prospects

  2014cited by this paper
• The Role of PAM4 in the Management of Pancreatic Cancer: Diagnosis, Radioimmunodetection, and Radioimmunotherapy

  2014cited by this paper
• Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology

  2014cited by this paper
• Peptides for diagnosis and treatment of colorectal cancer.

  2014cited by this paper
• A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

  2013cited by this paper
• Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

  2013cited by this paper
• Targeted radionuclide therapy--an overview.

  2013cited by this paper
• Radioimmunotherapy for hematopoietic cell transplantation.

  2013cited by this paper
• Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?

  2013cited by this paper
• Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

  2013cited by this paper
• 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.

  2013cited by this paper
• Advances in anticancer radiopharmaceuticals.

  2013cited by this paper
• Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.

  2013cited by this paper
• Alpha emitter radium-223 and survival in metastatic prostate cancer.

  2013cited by this paper
• Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.

  2013cited by this paper
• Radiation Biology: A Handbook for Teachers and Students

  2012cited by this paper
• Pretargeted Molecular Imaging and Radioimmunotherapy

  2012cited by this paper
• Optimizing radioimmunoconjugate delivery in the treatment of solid tumor.

  2012cited by this paper
• Systemic Targeted Alpha Radiotherapy for Cancer

  2012cited by this paper
• The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases.

  2012cited by this paper
• Rhenium-188: availability from the (188)W/(188)Re generator and status of current applications.

  2012cited by this paper
• Tumor Dosimetry Using [124I]m-iodobenzylguanidine MicroPET/CT for [131I]m-iodobenzylguanidine Treatment of Neuroblastoma in a Murine Xenograft Model

  2012cited by this paper
• Fractionated radioimmunotherapy with 90Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer

  2012cited by this paper
• Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies

  2012cited by this paper
• Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas.

  2012cited by this paper
• Effective use of strontium-89 in osseous metastases

  2012cited by this paper
• iodobenzylguanidine MicroPET/CT for ( 131 I)m-iodobenzylguanidine Treatment of Neuroblastoma in a Murine Xenograft Model

  2012cited by this paper
• Antibody therapy of cancer

  2012cited by this paper
• Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review

  2011cited by this paper
• Thyroid and hepatic function after high‐dose 131I‐metaiodobenzylguanidine (131I‐MIBG) therapy for neuroblastoma

  2011cited by this paper
• Feasibility of a novel positive feedback effect of 131I-promoted Bac–Egr1–hNIS expression in malignant glioma through baculovirus: a comparative study with Bac–CMV–hNIS

  2011cited by this paper
• Astatine-211: production and availability.

  2011cited by this paper
• Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

  2011cited by this paper
• Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma.

  2011cited by this paper
• MUC1 immunotherapy.

  2010cited by this paper
• Radioimmunotherapy of lymphoma: Bexxar and Zevalin.

  2010cited by this paper
• Antioxidative and Radiation Modulating Properties of Guanosine-5′-Monophosphate

  2010cited by this paper
• New Antibody Conjugates in Cancer Therapy

  2010cited by this paper
• NF-kappaB p65 subunit mediates lipopolysaccharide-induced Na(+)/I(-) symporter gene expression by involving functional interaction with the paired domain transcription factor Pax8.

  2010cited by this paper
• Sodium Iodide Symporter and the Radioiodine Treatment of Thyroid Carcinoma

  2010cited by this paper
• [Antibody therapy in cancer].

  2010cited by this paper
• Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case.

  2009cited by this paper
• Protection of mice against X-ray injuries by the post-irradiation administration of guanosine and inosine

  2009cited by this paper
• Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

  2009cited by this paper
• Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

  2008cited by this paper
• Anti-cancer therapies targeting the tumor stroma

  2007cited by this paper
• Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma

  2007cited by this paper
• The importance of sodium/iodide symporter (NIS) for thyroid cancer management.

  2007cited by this paper
• Guanosine and Inosine Display Antioxidant Activity, Protect DNA In Vitro from Oxidative Damage Induced by Reactive Oxygen Species, and Serve as Radioprotectors in Mice

  2006cited by this paper
• The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia.

  2006cited by this paper
• High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?

  2006cited by this paper
• Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.

  2006cited by this paper
• High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

  2006cited by this paper
• Radiobiologic principles in radionuclide therapy.

  2005cited by this paper
• Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.

  2005cited by this paper
• Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma

  2004cited by this paper
• Radioimmunotherapy with alpha-particle emitting radionuclides.

  2004cited by this paper
• Transcriptional regulation of human sodium/iodide symporter gene: a role for redox factor-1.

  2004cited by this paper
• HLA class II antibodies in the treatment of hematologic malignancies.

  2003cited by this paper
• Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

  2002cited by this paper
• Therapeutic radionuclides and nuclear data

  2001cited by this paper
• Anti-CD30 antibody–based therapy

  2000cited by this paper
• The AAPM/RSNA physics tutorial for residents: internal radiation dosimetry: principles and applications.

  2000cited by this paper
• Yttrium-90 biodistribution by yttrium-87 imaging: a theoretical feasibility analysis.

  1998cited by this paper
• Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells.

  1996cited by this paper
• Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy.

  1996cited by this paper
• Cloning and characterization of the thyroid iodide transporter

  1996cited by this paper

• Radioisotopes for Nuclear Medicine: An Overview

  2026cites this paper
• CopperNostics-Here We Are Now, Entertain Us!

  2026cites this paper
• DFT calculation of Ac3+ and Bi3+ complexation with hybrid chelator 3p-C-DEPA for targeted alpha therapy

  2026cites this paper
• Production of Diagnostic and Therapeutic Radionuclides with Uranium and Thorium Molten Salt Fuel Cycles

  2026cites this paper
• Evaluation of Daughter Radionuclide Release from the 103Pd/103mRh In Vivo Generator for Targeted Auger Therapy

  2026cites this paper
• Radiolabeled Vitamins and Nanosystems as Potential Agents in Oncology Theranostics: Developed Approaches and Future Perspectives

  2026cites this paper
• DNA-Encoded Libraries (DELs) for Discovering New Molecular Probes: Application to Live-Cell Bioimaging and Personalized Theranostics.

  2026cites this paper
• Radionuclide-Aided Improvement of the Therapeutic Efficacy of Novel Antibody-Drug Conjugates against HER2-Expressing Cancers.

  2025cites this paper
• Developing and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody.

  2025cites this paper
• Locoregional radionuclide therapy of glioblastoma with [211At]At-PDA-FAPI

  2025cites this paper
• Separation of radium from natural thorium by precipitation and barium carbonate co-precipitation

  2025cites this paper
• Clinical Evidence of Combining Radiopharmaceutical Therapy With Immune Checkpoint Inhibitors

  2025cites this paper
• Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer

  2025cites this paper
• Optimizing Cancer Treatment: Exploring the Role of AI in Radioimmunotherapy

  2025cites this paper
• Towards the Stable Chelation of Radioantimony(V) for Targeted Auger Theranostics.

  2025cites this paper
• Radiopharmaceuticals and their applications in medicine

  2025cites this paper
• Advances in Preclinical Research of Theranostic Radiopharmaceuticals in Nuclear Medicine.

  2025cites this paper
• The potential of gold nanoparticles in prostate-specific membrane antigen-targeted radioligand therapy for future treatment of metastatic castration-resistant prostate cancer

  2025cites this paper
• A Geant4-DNA study on DNA damage induced by 161Tb and 177Lu in a multicellular atomic model

  2025cites this paper
• Disphosphate based hydrogel microspheres for targeted transarterial radioembolization and chemoembolization therapies.

  2025cites this paper
• Advances in Nanobody-Based Platforms for Precision Cancer Diagnosis and Therapy

  2025cites this paper
• Enhanced tumor retention and therapeutic potency in radionuclide therapy using GSH-induced self-assembling peptides.

  2025cites this paper
• Evaluation of 134Ce/134La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer

  2025cites this paper
• Endovascular Applications for the Management of High-Grade Gliomas in the Modern Era

  2024cites this paper
• Biogenic nanoparticles as a promising drug delivery system

  2024cites this paper
• Mechanisms of Cancer Cell Radioresistance: Modern Trends and Research Prospects

  2024cites this paper
• Evaluation of Environmental Radiation Exposure and Algorithms for Determining the Occupational Effective Dose During 99mTc-MDP Bone Scintigraphy: A Comprehensive Analysis

  2024cites this paper
• Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide Therapy in Oncology

  2024cites this paper
• Comparison of the dosimetry and cell survival effect of 177Lu and 161Tb somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastases

  2024cites this paper
• The applications of radioisotopes in modern medicine: a review of diagnostic, therapeutic, and research advancements

  2024cites this paper
• Gastrin-releasing peptide receptor as theranostic target in estrogen-receptor positive breast cancer: A preclinical study of the theranostic pair [55Co]Co- and [177Lu]Lu-DOTA-RM26.

  2024cites this paper
• Unveiling the Therapeutic Potential of Folate-Dependent One-Carbon Metabolism in Cancer and Neurodegeneration

  2024cites this paper
• Image-Guided Mesenchymal Stem Cell Sodium Iodide Symporter (NIS) Radionuclide Therapy for Glioblastoma

  2024cites this paper
• Laser fragmentation of amorphous and crystalline selenium of various morphologies and assessment of their antioxidant and protection properties

  2024cites this paper
• The Rational Engineered Bacteria Based Biohybrid Living System for Tumor Therapy

  2024cites this paper
• Cenosphere‐Based 177Lu‐Aluminosilicate Microspheres as a Theranostic β‐Emitter for Selective Internal Radiation Therapy of Hepatic Tumors

  2024cites this paper
• Targeted delivery of activatable 131I-radiopharmaceutical for sustained radiotherapy with improved pharmacokinetics.

  2024cites this paper
• Functional hydrogels for hepatocellular carcinoma: therapy, imaging, and in vitro model

  2024cites this paper
• 225Ac/213Bi radionuclide generators for the separation of 213Bi towards clinical demands

  2024cites this paper
• Strategies for overcoming tumour resistance to immunotherapy: harnessing the power of radiation therapy

  2024cites this paper
• Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues

  2024cites this paper
• CdTe XG-Cam: A new high-resolution x-ray and gamma-ray camera for studies of the pharmacokinetics of radiopharmaceuticals in small animals.

  2024cites this paper
• Brain Metastasis: an insight into novel molecular targets for theranostic approaches.

  2024cites this paper
• Optimization of Monte Carlo Method-Based QSPR modeling for lipophilicity in radiopharmaceuticals

  2024cites this paper
• Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium

  2024cites this paper
• Gastrin-releasing peptide receptor as a theranostic target in breast cancer: a systematic scoping review.

  2024cites this paper
• The application of radionuclide therapy for breast cancer

  2024cites this paper
• Carrier systems of radiopharmaceuticals and the application in cancer therapy

  2024cites this paper
• Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation

  2024cites this paper
• Evaluation of Therapeutic Efficacy and Imaging Capabilities of 153Sm2O3-Loaded Polystyrene Microspheres for Intra-Tumoural Radionuclide Therapy of Liver Cancer Using Sprague-Dawley Rat Model

  2023cites this paper
• Resonant laser ionization and mass separation of 225Ac

  2023influential citation
• Comparative Study of the Effect of Radiation Delivered by Lutetium-177 or Actinium-225 on Anti-GD2 Chimeric Antigen Receptor T Cell Viability and Functions

  2023cites this paper
• DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair

  2023cites this paper
• Synthesis and biological evaluation of bi-modal BODIPY-conjugated Hoechst applicable for Auger-electron and photodynamic cancer therapy.

  2023cites this paper
• Clinical Review of the Current Status and Utility of Targeted Alpha Therapy

  2023cites this paper
• Study of thulium-167 cyclotron production: a potential medically-relevant radionuclide

  2023cites this paper
• Head‐to‐head comparison of three chelates reveals DOTAGA promising for 225Ac labeling of anti‐FZD10 antibody OTSA101

  2023cites this paper
• Developments in 177Lu-based radiopharmaceutical therapy and dosimetry

  2023cites this paper
• A GATE simulation study for dosimetry in cancer cell and micrometastasis from the 225Ac decay chain

  2023cites this paper
• Opportunities and challenges of low-dose radiation to enable immunotherapy efficacy.

  2023cites this paper
• Modifications in cellular viability, DNA damage and stress responses inflicted in cancer cells by copper-64 ions

  2023cites this paper
• Immunohistochemical expression of CD117/KIT, HER2, and Erβ in schistosomal and non-schistosomal urothelial carcinoma of Egyptian patients

  2023cites this paper
• An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy

  2023cites this paper
• Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy

  2023cites this paper
• Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update.

  2023cites this paper
• Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry

  2023cites this paper
• Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics

  2023cites this paper
• Radionuclide-based theranostics — a promising strategy for lung cancer

  2023cites this paper
• ANALYSIS OF THE PRODUCTION OF RARE-EARTH ISOTOPES AT THE WWR-K RESEARCH REACTOR: PROMISING THERAPEUTIC RADIONUCLIDES

  2023cites this paper
• Development of a multifunctional platform for near-infrared imaging and targeted radionuclide therapy for tumors.

  2023cites this paper
• A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy.

  2022cites this paper
• Roles of Podoplanin in Malignant Progression of Tumor

  2022cites this paper
• Estimation of the Internal Dose Imparted by 18F-Fluorodeoxyglucose to Tissues by Using Fricke Dosimetry in a Phantom and Positron Emission Tomography

  2022cites this paper
• Calcium carbonate carriers for combined chemo- and radionuclide therapy of metastatic lung cancer.

  2022cites this paper
• Design and Evaluation of Novel Albumin-Binding Folate Radioconjugates: Systematic Approach of Varying the Linker Entities.

  2022cites this paper
• A Monte Carlo study on the effects of a static uniform magnetic field on micro-scale dosimetry of Auger-emitters using Geant4-DNA

  2022cites this paper
• Legumain-mediated self-assembly of a 131I-labelled agent for targeted radiotherapy of tumors.

  2022cites this paper
• Modulation of Secondary Cancer Risks from Radiation Exposure by Sex, Age and Gonadal Hormone Status: Progress, Opportunities and Challenges

  2022cites this paper
• First Demonstration of Domestic Large-Scale Production of 177Lu for Advanced Cancer Therapy

  2022cites this paper
• Oncostatin M Receptor as a Therapeutic Target for Radioimmune Therapy in Synovial Sarcoma

  2022cites this paper
• Challenges and opportunities in developing Actinium-225 radiopharmaceuticals

  2022cites this paper
• Palmitic Acid-Conjugated Radiopharmaceutical for Integrin αvβ3-Targeted Radionuclide Therapy

  2022cites this paper
• PROSPECTS FOR THE DEVELOPMENT OF NUCLEAR MEDICINE IN THE REPUBLIC OF KAZAKHSTAN: REACTOR ISOTOPES OF RARE EARTH ELEMENTS FOR THERAPY

  2022cites this paper
• Emerging applications of nanobodies in cancer therapy.

  2022cites this paper
• Dosimetry assessment of theranostic Auger-emitting radionuclides in a micron-sized multicellular cluster model: A Monte Carlo study using Geant4-DNA simulations.

  2022cites this paper
• Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide

  2022cites this paper
• Core–shell structured gold nanoparticles as carrier for 166Dy/166Ho in vivo generator

  2022cites this paper
• Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review

  2022influential citation
• Exploring Nitric Oxide (NO)-Releasing Celecoxib Derivatives as Modulators of Radioresponse in Pheochromocytoma Cells

  2022cites this paper
• Discovery, nuclear properties, synthesis and applications of technetium-101

  2022cites this paper
• Optimizing and determining the click chemistry mediated Cu-64 radiolabeling and physiochemical characteristics of trastuzumab conjugates.

  2022cites this paper
• The effect of iodine-131 beta-particles in combination with A-966492 and Topotecan on radio-sensitization of glioblastoma: An in-vitro study.

  2021cites this paper
• The effects of mismatch between SPECT and CT images on quantitative activity estimation – A simulation study

  2021cites this paper
• Fusion-Based Neutron Generator Production of Tc-99m and Tc-101: A Prospective Avenue to Technetium Theranostics

  2021cites this paper
• Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma

  2021cites this paper
• Impact of metallic coating on the retention of 225Ac and its daugthers within core-shell nanocarriers.

  2021cites this paper
• Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC)

  2021cites this paper
• Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review

  2021cites this paper
• Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma

  2021cites this paper
• Radiolabeled carbon-based nanostructures: New radiopharmaceuticals for cancer therapy?

  2021cites this paper